Ontology highlight
ABSTRACT:
SUBMITTER: Kim HD
PROVIDER: S-EPMC10957471 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
Kim Hyung-Don HD Jung Seyoung S Lim Ho Yeong HY Ryoo Baek-Yeol BY Ryu Min-Hee MH Chuah Samuel S Chon Hong Jae HJ Kang Beodeul B Hong Jung Yong JY Lee Han Chu HC Moon Deok-Bog DB Kim Ki-Hun KH Kim Tae Won TW Tai David D Chew Valerie V Lee Jeong Seok JS Finn Richard S RS Koh June-Young JY Yoo Changhoon C
Nature medicine 20240219 3
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib-nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule ...[more]